Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Biomarker Development Critical to Continued Progress in NSCLC

March 24th 2018

Jeffrey Melson Clarke, MD, discusses the latest developments with biomarkers in NSCLC.

Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021

March 23rd 2018

Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.

Dr. Goldberg Discusses Osimertinib in NSCLC

March 23rd 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non–small cell lung cancer.

Rova-T Underperforms in Phase II SCLC Trial

March 23rd 2018

Rovalpituzumab Tesirine (Rova-T) delivered disappointing preliminary results in the third-line setting for patients with relapsed/refractory small cell lung cancer with high DLL3 expression.

Dr. Wakelee Discusses EGFR TKIs in Lung Cancer

March 21st 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Atezolizumab Plus Chemo Improves PFS in Frontline Squamous NSCLC

March 20th 2018

The addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer.

Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

March 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Dr. Kim Addresses Concerns About Hyperprogression in NSCLC

March 14th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the prevalence of hyperprogression and pseudoprogression in patients who receive immunotherapy.

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14th 2018

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Locally Advanced NSCLC: Audience Q&A

March 13th 2018

Promising Developments in Locally Advanced NSCLC

March 13th 2018

Improving Care in Locally Advanced NSCLC

March 13th 2018

Tips for Managing NSCLC Patients on Durvalumab Therapy

March 13th 2018

NSCLC: Consolidation Immunotherapy in Practice

March 13th 2018

Chemotherapy Choices in the PACIFIC Trial

March 13th 2018

PACIFIC Trial: A Game Changer in Unresectable LA NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Overview

March 13th 2018

Key Considerations in the Management of Stage 3 NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Goals and Challenges

March 13th 2018